Jazz Pharmaceuticals PLC (JAZZ)
| Market Cap | 9.40B |
| Revenue (ttm) | 2.36B |
| Net Income (ttm) | 238.62M |
| Shares Out | 56.33M |
| EPS (ttm) | 4.22 |
| PE Ratio | 39.83 |
| Forward PE | 10.60 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 20 |
| Last Price | $168.09 |
| Previous Close | $167.16 |
| Change ($) | 0.93 |
| Change (%) | 0.56% |
| Day's Open | 165.41 |
| Day's Range | 164.01 - 168.40 |
| Day's Volume | 561,981 |
| 52-Week Range | 101.81 - 178.64 |
DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company") announced today that its wholly owned subsidiary, Jazz Securities Designated Activity Company (the "Issuer"...
DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates) ora...
DUBLIN, April 19, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 first quarter financial results on Tuesday, May 4, 2021 after the close of the...
JAZZ focuses on expanding label of its recently approved sleep drug, Xywav - a low sodium-formulation of Xyrem.
DUBLIN, April 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation and confirmed the ...
2020 was a big year for the cannabis industry, but 2021 is shaping up to be even bigger.
Although research on the medical benefits of the drug is limited in the U.S., we have some ideas about marijuana's ability to disrupt the healthcare industry.
Cannabinoid-based medicines have made major advancements in research and uptake over the past few years.
Jazz Pharmaceuticals (JAZZ) gets FDA approval for label expansion of its cancer drug, Vyxeos, in pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia.
DUBLIN, March 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos® (daunorubicin and cyt...
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
BZUN, EQR, FRPT, JAZZ, and SPTN have been added to the Zacks Rank #5 (Strong Sell) List on March 23, 2021
DUBLIN, March 22, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 10th Annual J.P. Morgan Napa Valley Forum.
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
DUBLIN, March 18, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and the Hypersomnia Foundation today announced the launch of I Have IH, a disease awareness campaign that aims to increase ...
But the low prices may not last for long, because these companies' futures look bright.
These are the top players in the expanding $19.6 billion U.S. marijuana market.
After soaring to all-time highs last month, exchange traded funds tracking cannabis stocks are coming back down to test a key support line. The post Don't Miss These 2 Ways To Play The Hot Marijuana Sto...
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will cont...
Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.
The company beat top-line estimates, but missed on the bottom line.
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 9.50% year over year to $4.00, which ...
DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Cowen 41st Annual Healthcare conference. Bru...
With many people seeking natural therapies to address pandemic-related stress, the backdrop is favorable for marijuana stocks. The post 8 Medical Marijuana Stocks That Are Just What the Doctor Ordered a...
Jazz Pharmaceuticals (NASDAQ:JAZZ) releases its next round of earnings this Tuesday, February 23. Here is Benzinga's essential guide to Jazz Pharmaceuticals's Q4 earnings report.
Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.
Increasingly, the Wall Street firms we cover are starting to agree that, while the future is still bright for the U.S.
Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) recently-announced deal to acquire cannabis-derived drug maker GW Pharmaceuticals plc (NASDAQ:GWPH) for US$7.2 billion in cash and stock has boosted investor int...
DUBLIN, Feb. 16, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food a...
DUBLIN, Feb. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 fourth quarter and full year financial results on Tuesday, February 23, 2021, af...
A blockbuster deal announced earlier this week could be a sign of a bright future for cannabidiol-oriented pharmaceutical companies. On Wednesday, cancer therapy developer Jazz Pharmaceuticals PLC (NASD...
Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) recently-announced deal to acquire cannabis-derived drug maker GW Pharmaceuticals plc (NASDAQ:GWPH) for US$7.2 billion in cash and stock has boosted investor int...
Jazz is paying $7.2 million to buy the maker of CBD-derived drug Epidiolex. Is it a smart deal?
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will deve...
This troubled biopharma is making a multi-billion dollar bet on the cannabis industry in hopes of a turnaround.
The deal to buy GW Pharmaceuticals creates a leader in neuroscience.
GW Pharmaceuticals (GWPH) stock is soaring higher on Wednesday following news that Jazz Pharmaceuticals (JAZZ) is acquiring the company. The post GWPH Stock: 12 Things to Know About the GW Pharma-Jazz P...
Marijuana stocks rallied as Jazz Pharmaceuticals said it would buy GW Pharma. GWPH stock jumped.
Jazz Pharmaceuticals Plc said on Wednesday it would buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal to bolster its neuroscience business by adding a cannabis-based epilepsy treatment.
About JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narc... [Read more...]
| Industry Biotechnology | IPO Date Jun 1, 2007 |
| Stock Exchange NASDAQ | Ticker Symbol JAZZ |
Financial Performance
In 2020, JAZZ's revenue was $2.36 billion, an increase of 9.34% compared to the previous year's $2.16 billion. Earnings were $238.62 million, a decrease of -54.41%.
Analyst Forecasts
According to 20 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is 202.53, which is an increase of 20.49% from the latest price.